Welcome to our dedicated page for Collplant Biotechnologies SEC filings (Ticker: CLGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CollPlant Biotechnologies Ltd. filings document foreign private issuer current reports for a regenerative and aesthetic medicine company built around plant-derived rhCollagen. Form 6-K reports cover operating and financial results, corporate updates on BioInk, Collink.3D, BioFlex, Vergenix STR and photocurable dermal filler technology, as well as intellectual-property disclosures and collaboration-related material events.
The filing record also documents capital-structure matters involving ordinary shares and warrants, Nasdaq Capital Market bid-price compliance notices, and material agreements. Certain 6-K reports are incorporated by reference into the company’s Form S-8 and Form F-3 registration statements, linking current-event disclosures to equity compensation and shelf-registration records.
CollPlant Biotechnologies (CLGN) filed a Form 6-K noting it issued a press release on October 16, 2025 titled “First-in-Kind Fully Humanized 3D Bioprinted Human Skin Model Developed by Mayo Clinic Researchers using CollPlant's rhCollagen-Based BioInk.” The notice highlights Mayo Clinic researchers’ work and references CollPlant’s rhCollagen-based BioInk. No additional operational or financial details are included in this filing excerpt.
CollPlant Biotechnologies Ltd (CLGN) filed a Form 144 notifying a proposed sale of 140,000 ordinary shares through UBS Securities LLC with an aggregate market value of $308,000. The filing lists 12,716,014 shares outstanding and an approximate sale date of 10/10/2025.
The shares were acquired in a private placement from the issuer on 10/27/2019 and payment was by wire transfer in US$ on the same date. The filer certifies no undisclosed material adverse information and reports no sales in the past three months.
CollPlant Biotechnologies Ltd (CLGN) Schedule 13D shows members of the Loewenbaum family and related trusts collectively beneficially own 1,698,533 ordinary shares, representing 13.4% of outstanding shares based on 12,716,014 shares outstanding as of June 30, 2025. Individual holdings disclosed include George W. Loewenbaum with 1,256,056 shares (9.9%), Lillian S. Loewenbaum with 186,289 shares (1.5%), and several trusts and entities holding the remainder. Recent open-market purchases in late July 2025 at prices from $2.25 to $2.41 are reported. The stated purpose is investment; no present plans to effect corporate changes, but the group will continue to review its position. A Joint Filing Agreement governs the filing.
CollPlant Biotechnologies Ltd. furnished a Form 6-K to provide investors with a press release dated September 30, 2025. In this release, the company reports positive results from non-clinical studies of its photocurable regenerative dermal and soft tissue filler, a product candidate in its regenerative medicine portfolio. The first and fourth paragraphs of the press release are also incorporated by reference into several of CollPlant’s effective shelf and employee incentive registration statements, so that the new information forms part of those securities offering documents.
CollPlant Biotechnologies Ltd. submitted a Form 6-K as a foreign private issuer, noting that it issued a press release on September 15, 2025 titled “CollPlant Expands the Distribution of its VergenixSTR Product in Europe.”
This filing mainly serves to formally furnish that press release to investors and the market under U.S. securities rules. It highlights CollPlant’s focus on expanding access to its VergenixSTR product in European markets, but does not itself include financial results or transaction details.
CollPlant Biotechnologies Ltd. filed a Form 6-K reporting that it has released its second quarter 2025 financial results and a corporate update. The company furnished a press release, unaudited condensed consolidated interim financial statements as of June 30, 2025, and an operating and financial review for the same period.
The filing also states that the financial results sections, balance sheet and cash flow information, accompanying consolidated financial statements, and forward-looking statements from these materials are incorporated by reference into CollPlant’s existing Form S-8 and Form F-3 registration statements, making them part of those offerings from the submission date.